Latest Earnings Results: Q3 '26
Estimated EPS
-$0.13
Reported EPS
-$0.10
Surprise
+22.22%
Estimated Rev
$0.76M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.10 down -11.11% YoY • Taysha expects its current cash resources of $422.8M to support planned operating expenses and capital requirements into the second half of 2028, as of September 30, 2026.
Bullish Takeaway
Taysha reported TSHA-102 was generally well tolerated, with no severe treatment-related SAEs or DLTs across 33 patients, completed PPQ meeting specifications and comparability criteria, and plans a second candidate nomination in 1H 2027.
Bearish Takeaway
Taysha's quarterly R&D and G&A expenses increased, net loss increased, revenue was zero, and TSHA-102 pivotal interim data and FDA feedback on the BLA pathway remain expected in 1H 2027.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.13 | -- | -- | N/A |
Q3 '26 | -$0.13 | -$0.10 | 22.22% | BEAT |
Q2 '26 | -$0.11 | -$0.13 | -14.76% | MISSED |
Q1 '26 | -$0.10 | -$0.12 | -24.14% | MISSED |
Q4 '25 | -$0.10 | -$0.08 | 16.32% | BEAT |